Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
RAPT Therapeutics, Inc. is the subject of an all‑cash tender offer by Redrose Acquisition Co., an entity controlled by GlaxoSmithKline, to acquire all outstanding common shares for $58.00 per share.
The filing states the Hart‑Scott‑Rodino waiting period expired February 23, 2026 and the "Regulatory Conditions to the Offer have been satisfied." The filing also reports that, as of February 24, 2026, two state‑court complaints were filed (Morgan and Walsh) alleging negligent misrepresentation and concealment related to the Schedule 14D‑9, and the Company received twelve demand letters alleging disclosure deficiencies.
RAPT Therapeutics, Inc. is the subject of an all‑cash tender offer by Redrose Acquisition Co., an entity controlled by GlaxoSmithKline, to acquire all outstanding common shares for $58.00 per share.
The filing states the Hart‑Scott‑Rodino waiting period expired February 23, 2026 and the "Regulatory Conditions to the Offer have been satisfied." The filing also reports that, as of February 24, 2026, two state‑court complaints were filed (Morgan and Walsh) alleging negligent misrepresentation and concealment related to the Schedule 14D‑9, and the Company received twelve demand letters alleging disclosure deficiencies.
GSK plc reports that, on 20 February 2026, it repurchased 467,000 ordinary shares of 31¼ pence each through BNP Paribas as part of its existing share buyback programme, at a volume-weighted average price of 2,223.53p, within a price range of 2,200.00p to 2,242.00p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 1,767,000 ordinary shares. Following this transaction, it holds 241,658,094 shares in treasury and has 4,074,494,332 ordinary shares in issue, which equals the total voting rights. Treasury shares represent 5.93% of voting rights.
GSK plc reports that, on 20 February 2026, it repurchased 467,000 ordinary shares of 31¼ pence each through BNP Paribas as part of its existing share buyback programme, at a volume-weighted average price of 2,223.53p, within a price range of 2,200.00p to 2,242.00p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought 1,767,000 ordinary shares. Following this transaction, it holds 241,658,094 shares in treasury and has 4,074,494,332 ordinary shares in issue, which equals the total voting rights. Treasury shares represent 5.93% of voting rights.
GSK plc reported a share purchase by one of its board members. Independent Non-Executive Director Wendy Becker bought 3,334 ordinary shares of GSK at a price of £22.1926 per share. The transaction took place on 20 February 2026 on the London Stock Exchange.
GSK plc reported a share purchase by one of its board members. Independent Non-Executive Director Wendy Becker bought 3,334 ordinary shares of GSK at a price of £22.1926 per share. The transaction took place on 20 February 2026 on the London Stock Exchange.
GSK plc reports that, acting through BNP Paribas, it bought back 470,000 ordinary shares of 31¼ pence each on 19 February 2026. The purchases were made at prices between 2,217.00p and 2,264.00p per share, with a volume-weighted average price of 2,243.09p.
The shares will be held as treasury shares under GSK’s existing buyback programme, pursuant to a non-discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has repurchased 1,300,000 shares. After this transaction, it holds 241,191,094 shares in treasury and has 4,074,951,475 shares in issue, which equals 4,074,951,475 voting rights. Treasury shares represent 5.92% of voting rights under the Disclosure Guidance and Transparency Rules.
GSK plc reports that, acting through BNP Paribas, it bought back 470,000 ordinary shares of 31¼ pence each on 19 February 2026. The purchases were made at prices between 2,217.00p and 2,264.00p per share, with a volume-weighted average price of 2,243.09p.
The shares will be held as treasury shares under GSK’s existing buyback programme, pursuant to a non-discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has repurchased 1,300,000 shares. After this transaction, it holds 241,191,094 shares in treasury and has 4,074,951,475 shares in issue, which equals 4,074,951,475 voting rights. Treasury shares represent 5.92% of voting rights under the Disclosure Guidance and Transparency Rules.
GSK plc reported a transaction involving Chief Scientific Officer Tony Wood related to its Deferred Investment Award Programme. On 18 February 2026, 25% of an award granted on 18 February 2021 vested. In connection with this vesting, Wood will receive a cash payment of £204,048.58, before tax, corresponding to 8,996.851 notional ordinary shares of 31¼ pence each, valued at £22.68 per share. This is recorded as a single transaction under GSK’s remuneration arrangements for senior management.
GSK plc reported a transaction involving Chief Scientific Officer Tony Wood related to its Deferred Investment Award Programme. On 18 February 2026, 25% of an award granted on 18 February 2021 vested. In connection with this vesting, Wood will receive a cash payment of £204,048.58, before tax, corresponding to 8,996.851 notional ordinary shares of 31¼ pence each, valued at £22.68 per share. This is recorded as a single transaction under GSK’s remuneration arrangements for senior management.
GSK plc reports that, acting through BNP Paribas, it repurchased 410,000 ordinary shares on 18 February 2026 as part of its existing share buyback programme. The shares, with a volume-weighted average price of 2,268.77p, will be held as treasury shares.
Since 17 February 2026, GSK has bought back a total of 830,000 ordinary shares. After these transactions, it holds 240,721,094 shares in treasury and has 4,075,421,475 ordinary shares in issue, which is also the total number of voting rights.
The company states that treasury shares now represent 5.91% of the voting rights. Detailed schedules list the prices and volumes of trades executed on the London Stock Exchange and Cboe Europe venues as part of this programme.
GSK plc reports that, acting through BNP Paribas, it repurchased 410,000 ordinary shares on 18 February 2026 as part of its existing share buyback programme. The shares, with a volume-weighted average price of 2,268.77p, will be held as treasury shares.
Since 17 February 2026, GSK has bought back a total of 830,000 ordinary shares. After these transactions, it holds 240,721,094 shares in treasury and has 4,075,421,475 ordinary shares in issue, which is also the total number of voting rights.
The company states that treasury shares now represent 5.91% of the voting rights. Detailed schedules list the prices and volumes of trades executed on the London Stock Exchange and Cboe Europe venues as part of this programme.
GSK plc repurchased 420,000 ordinary shares of 31¼ pence each on 17 February 2026, acting through BNP Paribas under a non-discretionary agreement as part of its existing share buyback programme. The shares were bought at prices between 2,189.00p and 2,259.00p, with a volume-weighted average price of 2,231.39p.
The repurchased shares will be held as treasury shares. After this transaction, GSK holds 240,311,094 ordinary shares in treasury and has 4,075,831,475 ordinary shares in issue excluding treasury shares, which is also the total number of voting rights. Treasury shares represent 5.90% of voting rights attributable to ordinary shares.
GSK plc repurchased 420,000 ordinary shares of 31¼ pence each on 17 February 2026, acting through BNP Paribas under a non-discretionary agreement as part of its existing share buyback programme. The shares were bought at prices between 2,189.00p and 2,259.00p, with a volume-weighted average price of 2,231.39p.
The repurchased shares will be held as treasury shares. After this transaction, GSK holds 240,311,094 ordinary shares in treasury and has 4,075,831,475 ordinary shares in issue excluding treasury shares, which is also the total number of voting rights. Treasury shares represent 5.90% of voting rights attributable to ordinary shares.
GSK plc reported a management share transaction involving President Maya Martinez-Davis. On February 13, 2026, performance share awards granted in 2020 under GSK’s 2017 Performance Share Plan vested, delivering 10,836.957 American Depositary Shares (ADS) at a price of $0.00 to the executive.
On the same date, 4,009.778 ADS were sold on the New York Stock Exchange at a price of $58.8509 per ADS to meet tax liabilities arising from the vesting. The remaining ADS from the award vesting continue to be held by the executive. These transactions reflect routine equity-based compensation and related tax settlement for a senior leader.
GSK plc reported a management share transaction involving President Maya Martinez-Davis. On February 13, 2026, performance share awards granted in 2020 under GSK’s 2017 Performance Share Plan vested, delivering 10,836.957 American Depositary Shares (ADS) at a price of $0.00 to the executive.
On the same date, 4,009.778 ADS were sold on the New York Stock Exchange at a price of $58.8509 per ADS to meet tax liabilities arising from the vesting. The remaining ADS from the award vesting continue to be held by the executive. These transactions reflect routine equity-based compensation and related tax settlement for a senior leader.
GSK plc reported that awards granted in 2023 under its 2017 Performance Share Plan for senior leaders vested at 82% of maximum, with 18% lapsing, after a three-year performance period to 31 December 2025. Vesting was driven by several business measures. Total sales over the period reached £99.03bn, above the £94.58bn level required for full vesting on that metric, while total profit was £30.22bn, above the £29.43bn 100% vesting hurdle. Total shareholder return ranked fifth in a peer group of 10 global pharmaceutical companies. Pipeline progress and responsible business environmental targets also achieved maximum vesting levels. On 13 February 2026, multiple PDMRs and one person closely associated received vested Ordinary Shares or ADS at no cost and sold portions at market prices, mainly around £21.6002 per Ordinary Share and $58.8509 per ADS, solely to meet tax liabilities.
GSK plc reported that awards granted in 2023 under its 2017 Performance Share Plan for senior leaders vested at 82% of maximum, with 18% lapsing, after a three-year performance period to 31 December 2025. Vesting was driven by several business measures. Total sales over the period reached £99.03bn, above the £94.58bn level required for full vesting on that metric, while total profit was £30.22bn, above the £29.43bn 100% vesting hurdle. Total shareholder return ranked fifth in a peer group of 10 global pharmaceutical companies. Pipeline progress and responsible business environmental targets also achieved maximum vesting levels. On 13 February 2026, multiple PDMRs and one person closely associated received vested Ordinary Shares or ADS at no cost and sold portions at market prices, mainly around £21.6002 per Ordinary Share and $58.8509 per ADS, solely to meet tax liabilities.
GSK plc is launching the fourth tranche of its previously announced £2 billion share buyback programme. This new tranche allows buybacks of up to £0.45 billion of ordinary shares, with purchases expected between 17 February 2026 and 24 April 2026.
GSK has entered a non-discretionary agreement with BNP Paribas S.A., which will independently execute trades on specified European venues. Shares repurchased in this tranche will be held as treasury shares. The programme is intended to return excess capital, reduce share capital, and is expected to enhance earnings per share.
The fourth tranche will be conducted within GSK’s existing authority to repurchase up to 413,957,879 ordinary shares granted at its 2025 Annual General Meeting, and will comply with applicable UK and EU-derived market regulations. No repurchases will be made in the United States or in respect of American Depositary Receipts.
GSK plc is launching the fourth tranche of its previously announced £2 billion share buyback programme. This new tranche allows buybacks of up to £0.45 billion of ordinary shares, with purchases expected between 17 February 2026 and 24 April 2026.
GSK has entered a non-discretionary agreement with BNP Paribas S.A., which will independently execute trades on specified European venues. Shares repurchased in this tranche will be held as treasury shares. The programme is intended to return excess capital, reduce share capital, and is expected to enhance earnings per share.
The fourth tranche will be conducted within GSK’s existing authority to repurchase up to 413,957,879 ordinary shares granted at its 2025 Annual General Meeting, and will comply with applicable UK and EU-derived market regulations. No repurchases will be made in the United States or in respect of American Depositary Receipts.